D
David R. Spriggs
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 40
Citations - 8031
David R. Spriggs is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Tumor necrosis factor alpha & Chemotherapy. The author has an hindex of 29, co-authored 37 publications receiving 7636 citations. Previous affiliations of David R. Spriggs include University of Wisconsin-Madison & Cornell University.
Papers
More filters
Journal ArticleDOI
Detection of circulating tumor necrosis factor after endotoxin administration.
Hamish R. Michie,Kirk R. Manogue,David R. Spriggs,Arthur Revhaug,S. T. O'Dwyer,Charles A. Dinarello,Anthony Cerami,Sheldon M. Wolff,Douglas W. Wilmore +8 more
TL;DR: It is concluded that the response to endotoxin is associated with a brief pulse of circulating tumor necrosis factor and that the resultant responses are effected through the cyclooxygenase pathway.
Journal ArticleDOI
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Martee L. Hensley,Robert G. Maki,Ennapadam Venkatraman,Gennifer Geller,Meghan Lovegren,Carol Aghajanian,Paul Sabbatini,William P. Tong,Richard Barakat,David R. Spriggs +9 more
TL;DR: Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS, and Hematologic toxicity was common, but neutropenic fever and bleeding events were rare.
Journal ArticleDOI
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation
TL;DR: It is reported that tumor necrosis factor alpha mRNA is increased after treatment with x-rays in certain human sarcoma cells, and production of TNF-alpha may add to radiation lethality through autocrine and paracrine mechanisms.
Journal Article
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Carol Aghajanian,Steven L. Soignet,Don S. Dizon,Christine S. Pien,Julian Adams,Peter J. Elliott,Paul Sabbatini,Vincent A. Miller,Martee L. Hensley,S. Pezzulli,Christina Canales,Adil Daud,David R. Spriggs +12 more
TL;DR: It is safe and reasonable to recommend treatment with PS341 on the schedule used in this trial at 1.56 mg/m2/dose in Phase II trials, and particular care should be taken with patients with preexisting neuropathy.
Journal Article
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings.
Hamish R. Michie,David R. Spriggs,Kirk R. Manogue,Matthew L. Sherman,Arthur Revhaug,S. T. O'Dwyer,K A Arthur,Charles A. Dinarello,Anthony Cerami,Sheldon M. Wolff +9 more
TL;DR: TNF may represent the primary afferent signal that initiates many of the metabolic responses associated with sepsis and endotoxemia.